

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Attorney Docket No.: 02-414-A1)

In re Application of: )  
Varghese John ) Examiner: Sahar Javanmard  
Serial No.: 10/517,979 )  
Filed: December 19, 2005 ) Art Unit: 1617  
For: Methods Of Treating ) Confirmation No.: 1935  
Alzheimer's Disease Using )  
Aryl Alkanoic Acid Amides )

**RESPONSE TO THE RESTRICTION REQUIREMENT**  
MAILED DECEMBER 28, 2007


Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This paper is responsive to the Restriction Requirement mailed December 28, 2007, in the subject application.

Elections of a compound species and a disease species from within claim 1 are required.

With respect to a compound species, Applicants elect the compound of Example 1 on page 123. That compound is named 2(R,S)-Methyl-4(S)-hydroxy-5(S)-amino-7(S)-isopropyl-8-(p-tert-butylphenyl)-octanoic acid (N-butyl)amide hydrochloride and can be represented by the following formula:



The elected species can be defined in terms of the variables in Claim 1 as follows:

R<sub>1</sub>, R<sub>2</sub>, and R<sub>4</sub> are all hydrogen;

R<sub>3</sub> is t-butyl;

X is methylene;

R<sub>5</sub> is isopropyl;

R<sub>6</sub> is amino;

R<sub>7</sub> is methyl; and

R<sub>8</sub> is butyl.

The claims that read on the compound species identified above are claims 1, 2, 5, 6, 23, and 25.

With respect to a disease from the list in claim 1, Applicants elect Alzheimer's disease.

The pending claims that read on the species of Alzheimer's disease are claims 1-7, 23, 25, and 27.

The Applicants invite the Examiner to contact the Applicants' undersigned representative at (312) 913-2136 if the Examiner believes that this would expedite prosecution of this application.

February 28, 2008

Respectfully submitted,  
By: Steven J. Sarussi  
Steven J. Sarussi  
Reg. No. 32784

McDonnell Boehnen  
Hulbert & Berghoff LLP  
300 S. Wacker Drive  
Chicago, IL 60606  
(312) 913-2136